Some targeting moieties such as ApoB, apolipoprotein E (ApoE), or some peptides corresponding to the LDLR-binding domain of ApoE or ApoB have been proven to be effective in LDLR-targeted therapy of neoplastic diseases [71,72]. The gene discussed is LDLR; the disease is neoplasm.